We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Marketing triumph?

23 October 2003 By Robert Cyran

The AngloSwedish drugs company increased Q3 sales despite $2bn in lost sales to generics. But Nexium, the franchise drug, looks like a shaky base upon which to build earnings.

This content is for Subscribers only

or
If you need assistance please email breakingviews.clientsupport@thomsonreuters.com
 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)

We need you to verify your email address to continue. Please check your email/junk folder for our verification request.

Click here to resend the verification email.